The Lancet Oncology (Carrie et al), has reported that the 112-month (5 years) follow-up of the French phase III GETUG-AFU 16 trial confirmed that there is an improved progression-free survival advantage with the addition of short-term androgen-deprivation therapy (ADT) to salvage radiotherapy in men with rising prostate-specific antigen (PSA) after radical prostatectomy for prostate cancer.
However, the analysis at five years showed no overall survival benefit, but this finding should still be considered immature. We will need to wait for ten- and fifteen-year data to be able to know if there is a survival advantage provided by adding ADT to salvage radiation.
All indications point to the increased efficacy of adding short term ADT to salvage radiation post radical prostatectomy failure.
Long-Term Follow-up of Salvage Short-Term ADT Plus Radiotherapy After Radical Prostatectomy
